Aligning Cultural and Financial Incentives for Clinical Trials
Clinical Trials Sunday, May 13th, 2012Iom.edu: May 4, 2012.
Participant in the activities of the Institute of Medicine Forum on Drug Discovery, Development, and Translation. This commentary was developed following the Forum’s November 2011 workshop to envision a transformed U.S. clinical trials enterprise.
Note: The views expressed in commentaries are those of the authors and not necessarily of the authors’ organizations or of the IOM. Commentaries are intended to help inform and stimulate discussion. They have not been subjected to the review procedures of the IOM and are not reports of the IOM or of the National Research Council.
One session of the November 2011 Institute of Medicine (IOM) workshop Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020 focused on the need to develop new economic models for clinical trials and to change the environment in which they currently operate (IOM, 2012). The rationale for this approach is the general agreement that the present climate, in which clinical trials are carried out in the United States, is too expensive and organizationally complicated, resulting in fewer trials being planned, performed, and completed in this country. This fact has serious implications for the U.S. population. The presenters were asked to suggest new approaches that could reverse this situation. Read more
